October 15, 2014 Synthetic Biologics Appoints Prominent Gastrointestinal (GI) Key Opinion Leaders to Irritable Bowel Syndrome (IBS) Clinical Advisory Board
September 16, 2014 Synthetic Biologics' Statin-Class Candidate for Constipation-Predominant Irritable Bowel Syndrome Detailed at Company's Investor Day
September 12, 2014 Synthetic Biologics Receives Orphan Drug Designation for SYN-005 Treatment for Whooping Cough (Pertussis)
September 11, 2014 Synthetic Biologics to Host Phase II Trimesta™ for Multiple Sclerosis Conference Call
September 10, 2014 Synthetic Biologics to Webcast September 16, 2014 Irritable Bowel Syndrome (IBS) Investor Day
September 8, 2014 Synthetic Biologics Highlights SYN-005 Data Presented at the 54th ICAAC from Novel Whooping Cough (Pertussis) Program
September 7, 2014 Synthetic Biologics Highlights New Data from C. difficile Program Presented at the 54th ICAAC
September 3, 2014 Synthetic Biologics to Present at the 16th Annual Rodman & Renshaw Global Investment Conference in New York City
September 2, 2014 Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections
